Explore 3 Stock Ideas & Industry Insights Download Free Report

Pfizer Inc

Healthcare US PFE

25.62USD
-0.42(1.61%)

Last update at 2026-06-08T20:27:00Z

Day Range

25.6026.21
LowHigh

52 Week Range

25.7649.43
LowHigh

Fundamentals

  • Previous Close 26.04
  • Market Cap160358.06M
  • Volume39882554
  • P/E Ratio15.52
  • Dividend Yield5.92%
  • EBITDA13945.00M
  • Revenue TTM68537.00M
  • Revenue Per Share TTM12.16
  • Gross Profit TTM 66233.00M
  • Diluted EPS TTM1.83

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 34729.00M 24311.00M 7497.00M 17682.00M 11885.00M
Minority interest -35.00000M -45.00000M 36.00M 29.00M 36.00M
Net income 31372.00M 21979.00M 7020.00M 16273.00M 11153.00M
Selling general administrative 14305.00M 12253.00M 11615.00M 14350.00M 14455.00M
Selling and marketing expenses - - 197.00M - -
Gross profit 65986.00M 50467.00M 33216.00M 41531.00M 42399.00M
Reconciled depreciation 3609.00M 3700.00M 4777.00M 6010.00M 6384.00M
Ebit 40030.00M 24833.00M 10630.00M 15137.00M 16519.00M
Ebitda 43639.00M 28533.00M 14066.00M 19747.00M 21412.00M
Depreciation and amortization 3609.00M 3700.00M 3436.00M 4610.00M 4893.00M
Non operating income net other -217.00000M 4878.00M -663.00000M 4508.00M -2116.00000M
Operating income 40030.00M 24833.00M 10630.00M 15137.00M 15045.00M
Other operating expenses 63058.00M 61053.00M 33148.00M 37829.00M 38602.00M
Interest expense 1238.00M 1291.00M 1449.00M 1574.00M 1316.00M
Tax provision 3328.00M 1852.00M 477.00M 1384.00M 706.00M
Interest income 1824.00M 560.00M 538.00M 226.00M 333.00M
Net interest income -987.00000M -1255.00000M -1376.00000M -1348.00000M -983.00000M
Extraordinary items 6.00M -434.00000M 2631.00M 326.00M 806.00M
Non recurring 2328.00M 802.00M 600.00M 747.00M 1044.00M
Other items - - - - -
Income tax expense 3328.00M 1852.00M 477.00M 1384.00M 706.00M
Total revenue 100330.00M 81288.00M 41908.00M 51750.00M 53647.00M
Total operating expenses 28714.00M 30232.00M 24456.00M 27610.00M 27354.00M
Cost of revenue 34344.00M 30821.00M 8692.00M 10219.00M 11248.00M
Total other income expense net -5301.00000M -522.00000M -3133.00000M 2545.00M -2178.00000M
Discontinued operations 6.00M -434.00000M 2631.00M 4.00M 10.00M
Net income from continuing ops 31401.00M 22459.00M 7021.00M 16298.00M 11179.00M
Net income applicable to common shares 31372.00M 21979.00M 9616.00M 16273.00M 11153.00M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 197206.00M 181477.00M 154229.00M 167488.00M 159422.00M
Intangible assets 43370.00M 25146.00M 28472.00M 35369.00M 35211.00M
Earning assets - - - - -
Other current assets 5017.00M 3820.00M 3439.00M 2601.00M 2461.00M
Total liab 101289.00M 104014.00M 90756.00M 104042.00M 95664.00M
Total stockholder equity 95661.00M 77201.00M 63238.00M 63143.00M 63407.00M
Deferred long term liab 1023.00M 349.00M 4063.00M 5578.00M 3700.00M
Other current liab 29864.00M 31785.00M 12639.00M 11090.00M 12639.00M
Common stock 476.00M 473.00M 470.00M 468.00M 467.00M
Capital stock 476.00M 473.00M 470.00M 485.00M 486.00M
Retained earnings 125656.00M 103394.00M 96770.00M 97670.00M 89554.00M
Other liab 23348.00M 22637.00M 26589.00M 29736.00M 30519.00M
Good will 51375.00M 49208.00M 49577.00M 58653.00M 53411.00M
Other assets 3.00M 2.00M -1.00000M 1.00M -1.00000M
Cash 416.00M 1944.00M 1784.00M 1305.00M 1139.00M
Cash and equivalents 416.00M 1944.00M 1784.00M 1121.00M 1139.00M
Total current liabilities 42138.00M 42671.00M 25920.00M 37304.00M 31858.00M
Current deferred revenue 2520.00M 3067.00M 6269.00M 5804.00M 5709.00M
Net debt 34454.00M 35054.00M 36490.00M 50840.00M 40126.00M
Short term debt 2945.00M 2241.00M 2703.00M 16190.00M 8836.00M
Short long term debt 2945.00M 2241.00M 2703.00M 16195.00M 8831.00M
Short long term debt total 34870.00M 36998.00M 38274.00M 52145.00M 41265.00M
Other stockholder equity -22167.00000M -20769.00000M -22314.00000M -23372.00000M -15358.00000M
Property plant equipment 19276.00M 17721.00M 13900.00M 13967.00M 13385.00M
Total current assets 51259.00M 59693.00M 35067.00M 32803.00M 49926.00M
Long term investments 15069.00M 21526.00M 20262.00M 20147.00M 2767.00M
Net tangible assets 95661.00M -104.00000M 63238.00M -30896.00000M -25656.00000M
Short term investments 22316.00M 29125.00M 10437.00M 8525.00M 17694.00M
Net receivables 14529.00M 15745.00M 11194.00M 12068.00M 11399.00M
Long term debt 32884.00M 36195.00M 37133.00M 35955.00M 32909.00M
Inventory 8981.00M 9059.00M 8046.00M 8283.00M 7508.00M
Accounts payable 6809.00M 5578.00M 4309.00M 4220.00M 4674.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity 256.00M 262.00M 235.00M 303.00M 351.00M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -8304.00000M -5897.00000M -11688.00000M -11640.00000M -11275.00000M
Additional paid in capital - - - - -
Common stock total equity 476.00M 473.00M 470.00M 468.00M 467.00M
Preferred stock total equity - - - 17.00M 19.00M
Retained earnings total equity 125656.00M 103394.00M 96770.00M 97670.00M 89554.00M
Treasury stock -113969.00000M -111361.00000M -110988.00000M -110801.00000M -101610.00000M
Accumulated amortization - - - - -
Non currrent assets other 13163.00M 7679.00M 4569.00M 4450.00M 2799.00M
Deferred long term asset charges - - - - -
Non current assets total 145944.00M 121782.00M 119163.00M 134685.00M 109497.00M
Capital lease obligations - - - - -
Long term debt total 32884.00M 36195.00M 37133.00M 35955.00M 32909.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 11125.00M -19517.00000M -2592.00000M 9304.00M 6434.00M
Change to liabilities -803.00000M 1242.00M 1856.00M -3034.00000M 451.00M
Total cashflows from investing activities -15783.00000M -22546.00000M -4271.00000M -3945.00000M 4525.00M
Net borrowings -3516.00000M -1103.00000M -12755.00000M 8764.00M -935.00000M
Total cash from financing activities -14834.00000M -9816.00000M -9649.00000M -8485.00000M -20441.00000M
Change to operating activities -6500.00000M 16498.00M 1357.00M -1675.00000M 4.00M
Net income 31401.00M 22459.00M 7021.00M 16302.00M 11188.00M
Change in cash -1515.00000M 158.00M 475.00M 125.00M -206.00000M
Begin period cash flow 1983.00M 1825.00M 1350.00M 1225.00M 1431.00M
End period cash flow 468.00M 1983.00M 1825.00M 1350.00M 1225.00M
Total cash from operating activities 29267.00M 32580.00M 14403.00M 12588.00M 15827.00M
Issuance of capital stock - - - - -
Depreciation 5064.00M 5191.00M 4777.00M 6010.00M 6384.00M
Other cashflows from investing activities -12547.00000M -318.00000M 573.00M -11074.00000M 134.00M
Dividends paid -8983.00000M -8729.00000M -8440.00000M -8043.00000M 7978.00M
Change to inventory 592.00M -1125.00000M -736.00000M -1050.00000M -717.00000M
Change to account receivables 261.00M -3811.00000M -1249.00000M -742.00000M -644.00000M
Sale purchase of stock -2000.00000M 0.00000M 425.00M -8865.00000M -12198.00000M
Other cashflows from financing activities 3556.00M 1013.00M 29120.00M -735.00000M -589.00000M
Change to netincome -2742.00000M -7307.00000M 2886.00M 2863.00M -222.00000M
Capital expenditures 3236.00M 2711.00M 2791.00M 2594.00M 2196.00M
Change receivables 261.00M -3811.00000M -1249.00000M -742.00000M -644.00000M
Cash flows other operating 26895.00M 21402.00M 6869.00M -7761.00000M -612.00000M
Exchange rate changes - - - - -
Cash and cash equivalents changes -1350.00000M 218.00M 483.00M 158.00M -89.00000M
Change in working capital -4456.00000M 12804.00M -275.00000M -4031.00000M -926.00000M
Stock based compensation 872.00M 1182.00M 756.00M 718.00M 949.00M
Other non cash items 150.00M -4763.00000M 3592.00M -7025.00000M 437.00M
Free cash flow 26031.00M 29869.00M 11612.00M 9994.00M 13631.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PFE
Pfizer Inc
-0.42 1.61% 25.62 15.52 9.60 2.31 1.61 2.56 9.54
LLY
Eli Lilly and Company
17.73 1.57% 1149.15 78.14 31.95 16.34 45.83 16.65 54.36
JNJ
Johnson & Johnson
-0.61 0.26% 232.16 29.17 14.33 3.74 5.18 3.80 15.22
ABBV
AbbVie Inc
-4.16 1.83% 223.07 86.32 14.33 5.89 50.46 7.04 24.44
AZN
AstraZeneca PLC
-4.4 2.37% 181.55 30.69 19.23 5.30 6.45 5.72 17.23

Reports Covered

Stock Research & News

Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Pfizer Inc

235 East 42nd Street, New York, NY, United States, 10017

Key Executives

Name Title Year Born
Dr. Albert Bourla D.V.M., DVM, Ph.D. Chairman & CEO 1962
Mr. Frank A. D'Amelio CFO & Exec. VP 1958
Dr. Mikael Dolsten M.D., Ph.D. Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical 1958
Mr. Douglas M. Lankler Exec. VP & Gen. Counsel 1966
Mr. John D. Young Advisor 1965
Ms. Angela Hwang Chief Commercial Officer & Pres of Global Biopharmaceuticals Bus. 1966
Mr. David M. Denton Chief Financial Officer & Exec. VP 1965
Ms. Jennifer B. Damico Sr. VP, Controller & Principal Accounting Officer 1968
Ms. Lidia L. Fonseca Exec. VP and Chief Digital & Technology Officer 1969
Mr. Christopher J. Stevo CFA Sr. VP & Chief Investor Relations Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions